bortezomib + bendamustine

Bortezomib + bendamustine is a chemotherapy combination used primarily in multiple myeloma and certain non-Hodgkin lymphomas. Bortezomib is a reversible 26S proteasome inhibitor that disrupts proteasomal degradation, leading to accumulation of pro-apoptotic proteins and apoptosis in malignant plasma and lymphoma cells. Bendamustine is a bifunctional alkylating agent (nitrogen mustard with benzimidazole ring) that induces DNA crosslinks and strand breaks, inhibiting DNA replication and triggering apoptosis. The combination has been investigated in newly diagnosed and relapsed/refractory multiple myeloma, and in indolent and mantle cell lymphomas, often with corticosteroids or rituximab in extended regimens. It is not a fixed-dose co-formulation; it is administered as two separate injectable drugs within a regimen.

Other names

BVDbendamustine + bortezomib